SCHEMBL732774

SCHEMBL732774

CCOc1cc(C(=O)O)cc(OCC)c1-c1cnoc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.44
BRD4 O60885 2/20 0.41
BRD2 P25440 2/20 0.41
CREBBP Q92793 2/20 0.41
POLB P06746 3/20 0.41
ALOX15 P16050 1/20 0.41
HTT P42858 1/20 0.41
MAPT P10636 1/20 0.40
CASP6 P55212 1/20 0.39
CNR2 P34972 1/20 0.39
LMNA P02545 2/20 0.37
MRGPRX4 Q96LA9 1/20 0.37
HSD17B10 Q99714 1/20 0.37
SSTR5 P35346 2/20 0.37
KDM4E B2RXH2 1/20 0.36
TTR P02766 1/20 0.36
MEN1 O00255 1/20 0.36
GAA P10253 1/20 0.36
KMT2A Q03164 1/20 0.36
MCL1 Q07820 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL730974 0.86 S1PR1 (0.42) TSHRCREBBPHTTMAPTCNR2
SCHEMBL15178386 0.80 CNR2 (0.47) TSHRCREBBPPOLBMAPTCNR2
SCHEMBL731315 0.76 ROCK2 (0.47) TSHRBRD4BRD2CREBBPPOLB
SCHEMBL733080 0.75 LMNA (0.33) LMNA
SCHEMBL731308 0.74 MAP4K4 (0.45) TSHRPOLBALOX15HTTMAPT
SCHEMBL731949 0.74 TSHR (0.47) TSHRPOLBALOX15HTTMAPT
SCHEMBL731564 0.71 TSHR (0.47) TSHRCREBBPPOLBALOX15HTT
SCHEMBL730596 0.71 TSHR (0.41) TSHRBRD4BRD2CREBBPPOLB
SCHEMBL1501518 0.70 TSHR (0.56) TSHRCREBBPPOLBMAPTCASP6
SCHEMBL731007 0.70 TSHR (0.49) TSHRCNR2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2120569-B1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME (US) 2013-08-14 EP disclosed
EP-2120569-B1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME (US) 2013-08-14 EP disclosed
US-8138197-B2 Spirochromanon derivatives MSD K.K. (JP) 2012-03-20 US disclosed
US-8138197-B2 Spirochromanon derivatives MSD K.K. (JP) 2012-03-20 US disclosed
US-8138197-B2 Spirochromanon derivatives MSD K.K. (JP) 2012-03-20 US disclosed
EP-2120569-A2 SPIROCHROMANON DERIVATIVES Merck & Co., Inc. (US) 2009-11-25 EP disclosed
US-20090270436-A1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME LLC 2009-10-29 US disclosed
US-20090270436-A1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME LLC 2009-10-29 US disclosed
US-20090270436-A1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME LLC 2009-10-29 US disclosed
WO-2008088692-A2 SPIROCHROMANON DERIVATIVES MERCK & CO., INC. (US) 2008-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270436-A1 SPIROCHROMANON DERIVATIVES AKR1C3, CBR3, AKR1C4 TSHR 680/4885BRD4 67/4885BRD2 953/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.